Skip to main content
Equibles
IDYA logo

IDYA · IDEAYA Biosciences, Inc.

Track IDYA — free

Use IDYA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research IDYA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$38.06 +0.70 (+1.87%)
Russell 2000 member Rebalance outlook locked
Market Cap
$3.54B
Shares
96.49M
Volume · Oct 5 658K Avg daily vol (3M) 828.49K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$37.36 Open$38.52 Day$37.00–38.54 52W close$26.24–42.48 Avg vol 30d827K Short int9.9M · 10.3% float · 17.3d Short vol83% Last earningsNov 4, 2024 DataJan 2020–Oct 2026 Filing10-Q · Aug 4

Up next

Latest filing: 10-Q
filed Aug 4, 2026
Q4 2021 earnings call transcript
call held Mar 15, 2022

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$175.02M
Trailing 12 months
Revenue growth YoY
+3,024.4%
Year over year
Operating margin
-72.8%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-3.2%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$828.96M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+4.1%
Year over year · more shares
Price change (1Y)
+37.4%
Trailing year
Short interest
10.3%
Latest settlement · 17.3 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Neutral Momentum Strong Sentiment Bullish Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 15.3 · calm Equity put/call 0.58
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg +10%
above
Price vs 50-day avg −2%
below
RSI (14) 45
neutral
MACD trend Negative
52-week position 68%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Strong
1-month return −7%
trailing
6-month return +14%
trailing
YTD return +8%
this year
Relative strength +2%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $38 › 200d $34 — 50d above 200d
Institutional flow Accumulating
1 of 287 funds reported for Sep 30 · net +25 sh shares
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
10.29% of float · ▼ -1.7% MoM · 17.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
287 holders — near 3-yr high, broad support
Squeeze score 67
elevated · 0–100
Fundamentals
Strong
Revenue growth +3024%
Y/Y
EPS growth +62%
Y/Y
Free cash flow $-73.5M
Quant / Vol
risk profile
Very High
Volatility 46%
annualized · 1-yr
Max drawdown −27%
past year
ATR 4.0%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
1 · 5 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+10% Bullish
Price vs 50-day avg
−2% Neutral
RSI (14)
45 Neutral
MACD trend
Negative Bearish
52-week position
68% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $38 › 200d $34 — 50d above 200d
Institutional flow Accumulating
1 of 287 funds reported for Sep 30 · net +25 sh shares
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
10.29% of float · ▼ -1.7% MoM · 17.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
287 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $26 Now $37 · 68% Range high $42
vs 200-day avg +10% vs 50-day avg -2%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
IDYA
IDEAYA Biosciences, Inc.
this stock
$3.54B +8.1% +3024.4% — 10.3%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $133.37B +11.3% +46.2% 30.7 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
 $81.13B -4.8% +20.8% 19.5 2.5%
MRNA
Moderna, Inc.
 $79.40B +544.3% +4.3% — 8.2%
CSLLY
Csl Ltd
 $61.25B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
287
% held
106.7%
Reported
1 of 287
Top holder
FMR LLC
Held Float
View
Held by Funds
Fund positions
265
View
Short & Settlement
Short Interest Falling
Shares short
9.9M
Days to cover
17.3d
Change
-172.1K sh
View
Short Volume
Short vol %
83%
As of
Oct 2, 2026
Short Total
View
Fails to Deliver
FTD shares
19
Value
$759
As of
Sep 2, 2026
View
Off-Exchange
Off-exchange %
40.6%
Week of
Aug 31, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$218.7M
Net income (FY)
$-113.7M
EPS diluted
$-1.28
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Sep 14, 2026
This year
20
View
Proposed Sales
Value
$3.0M
Shares
75.0K
Filed
Aug 26, 2024
View
Earnings & Events
Webcasts
Last webcast
Sep 14, 2026
View
Investor Relations
Upcoming events
1
View

Performance

5D 20D 120D MTD YTD
IDYA +1.8% -6.5% +13.8% -2.8% +8.1%
SPY -0.2% -0.5% +12.2% +0.9% +12.9%
vs SPY +2.1% -6.1% +1.7% -3.7% -4.8%
Key facts CIK 1676725 CUSIP 45166A102 13F (30d) 5 filings 5 filers Visit website Investor relations